Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Treprostinil dry powder - Liquidia Technologies

Next Previous
X
Search
Drug Profile

Treprostinil dry powder - Liquidia Technologies

Alternative Names: LIQ-861; YUTREPIA

Latest Information Update: 28 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Liquidia Technologies
  • Class Acetic acids; Antifibrotics; Antihypertensives; Cyclopentanes; Naphthalenes; Prostaglandins; Skin disorder therapies; Small molecules; Vasodilators
  • Mechanism of Action Epoprostenol receptor agonists; Platelet aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Pulmonary arterial hypertension

Most Recent Events

  • 22 Aug 2024 Liquidia Corporation files litigation in the US District Court of the District of Columbia, to challenge regulatory exclusivity to Tyvaso DPI®, blocking access to treprostinil inhalation powder for Pulmonary arterial hypertension
  • 19 Aug 2024 US FDA grants tentative approval to Treprostinil dry powder for Pulmonary arterial hypertension and Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
  • 03 Jun 2024 The Federal Circuit denied the motion for preliminary injunction filed by United Therapeutics (UTHR) to block the launch of treprostinil inhalation powder

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top